Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOHDR-B: Neoadjuvant HDR Brachytherapy Prior to RALP for High-Risk Prostate Cancer
NCT07182279Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoints: Incidence of Adverse Events at 2 years and Treatment Completion at 2 years. Started Aug 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07182279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182279.